Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cancer Research UK spin-out gets US approval to trial unique T... June 18, 2021 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 The European Parliament’s Reports Include Several ESMO Asks and Materially Strengthen... July 15, 2026 How Adolescent and Young Adult Cancer Survivors Can Cope With the... November 17, 2022 Load more HOT NEWS FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk... Advances in Gynaecological Cancer Research Could Change the Treatment Landscape FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T...
